

GRIFOLS

Grifols to double Revolving Credit Facility to \$2 billion following strong support from global bank syndicate

- *Commitments for a new Revolving Credit Facility would more than double RCF size from \$938 million to approximately \$2 billion*
- *The new 6.5yr facility considerably strengthens Grifols' financial flexibility*
- *Margin would reduce from 300bps to 200bps, with potential further margin reduction to 125bps subject to deleveraging progress*
- *Demand from global banks significantly exceeded the final allocation*
- *The transaction follows recent positive rating actions from major credit rating agencies, reflecting significant confidence in Grifols' improving financial profile and deleveraging trajectory*

Barcelona, Spain, March 16, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative healthcare solutions, has received commitments from banks for a new Revolving Credit Facility (RCF) of approximately \$2 billion supported by a syndicate of leading international banks. This new facility would more than double the size of the previous \$938 million RCF and have a maturity of 6.5 years, further strengthening Grifols' financial flexibility and balance sheet. The new facility is subject to completion of the refinancing of the company's existing Term Loan B (TLB) by 31 May 2026, consistent with the company's announced plans.

Pursuant to the commitments, the margin applicable to the new facility would be reduced from 300 basis points to 200 basis points, with the potential to decline further to 125 bps subject to the company progressing on its deleveraging targets.

Demand from lenders to participate in the new facility significantly exceeded the final allocation of commitments, underscoring strong support for Grifols' deleveraging and free cashflow improvement progress from a group of global banks after completion of their due diligence and final approvals. The Joint Arrangers selected include Bank of America, JPMorgan, Santander, DNB, Citibank, Commerzbank, Deutsche Bank, Goldman Sachs Bank Europe SE, HSBC, Helaba, UBS, ING and Nomura.

Rahul Srinivasan, Chief Financial Officer of Grifols, said: "The significant upsize and attractive terms of the new RCF facility is further validation of Grifols' highly differentiated strategy and unique positioning, that has been many years in the making, and will support our continued Revenue growth, EBITDA growth and margin improvement, enhanced free cash flow generation and deleveraging path."

Strong re-rating momentum recognised by credit rating agencies

Recent positive rating actions by major credit agencies have recognised Grifols' improving operating performance, stronger cash flow generation and significant progress on deleveraging.

GRIFOLS

Notably, S&P Global Ratings has upgraded the company's issuer credit rating by two notches in the last 18 months to BB- with a stable outlook. Similarly, Moody's and Fitch Ratings have also improved Grifols rating and / or outlook, highlighting the company's strengthening financial profile, improving leverage trajectory and continued progress in restoring balance sheet strength.*

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

* A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.

GRIFOLS

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel: +34 93 571 00 02

INVESTORS:

Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21